Harvard Bioscience Inc Revenue Growth Rates (HBIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Harvard Bioscience Inc   (NASDAQ: HBIO)
 

HBIO's Revenue Growth by Quarter and Year

Harvard Bioscience Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HBIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 22.73
1st Quarter March 20.24
FY 42.97

HBIOs Annual Revenue
Harvard Bioscience Inc 's Revenue in the fiscal year 2025 $ 85.91 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2024 $ 93.77 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2023 $ 112.07 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2022 $ 113.34 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2021 $ 118.90 millions




HBIO Revenue second quarter 2026 Y/Y Growth Comment
Harvard Bioscience Inc achieved in the second quarter 2026, above Company average Revenue increase of 16.37% year on year, to $ 22.73 millions.

Looking into second quarter 2026 results within Laboratory Analytical Instruments industry 3 other companies have achieved higher Revenue growth. While Harvard Bioscience Inc ' s Revenue growth of 16.37% ranks overall at the positon no. 1211 in the second quarter 2026.


HBIO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -3.23 % -9.37 % 0.95 %
3rd Quarter September - -8.04 % -11.97 % -8.14 %
2nd Quarter June 16.37 % -12.11 % -22.5 % -1.85 %
1st Quarter March -4.44 % -10.9 % -20.71 % 4.17 %
FY   - -8.39 % -16.34 % -

Financial Statements
Harvard Bioscience Inc 's second quarter 2026 Revenue $ 22.73 millions HBIO's Income Statement
Harvard Bioscience Inc 's second quarter 2025 Revenue $ 19.53 millions Quarterly HBIO's Income Statement


HBIO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 25.72 % 19.48 % 16.05 %
3rd Quarter September - 2.51 % -2.03 % -13.74 %
2nd Quarter June 12.29 % -7.79 % -6.52 % -4.37 %
1st Quarter March -19.59 % -18.57 % -17.18 % 5.45 %
FY (Year on Year)   - -8.39 % -16.34 % -


Back to HBIO Growth rate Comparisons >> Back to HBIO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #4
Healthcare Sector #222
Overall #1211

Revenue Y/Y Growth Statistics
High Average Low
56.42 % -0.6 % -22.51 %
(Dec 31 2018)   (Dec 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #4
Healthcare Sector #222
Overall #1211
Revenue Y/Y Growth Statistics
High Average Low
56.42 % -0.6 % -22.51 %
(Dec 31 2018)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Harvard Bioscience Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.48 % -23.25 %
(Dec 31 2020)  


HBIO's II. Quarter Q/Q Revenue Comment
Harvard Bioscience Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.29%, to $ 22.73 millions, from $20.24 millions in the first quarter.
HBIO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 721.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #120
Overall #721
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #120
Overall #721
Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.48 % -23.25 %
(Dec 31 2020)  


HBIO's II. Quarter Q/Q Revenue Comment
Harvard Bioscience Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.29%, to $ 22.73 millions, from $20.24 millions in the first quarter.
HBIO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 721.


Harvard Bioscience Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 88.16 $ 84.97 $ 85.91 $ 86.75 $ 88.49
Y / Y Revenue Growth (TTM) -0.37 % -6.81 % -8.38 % -10.06 % -10.98 %
Year on Year Revenue Growth Overall Ranking # 3190 # 2340 # 2605 # 2980 # 2521
Seqeuential Revenue Change (TTM) 3.76 % -1.09 % -0.97 % -1.97 % -2.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 2838 # 2413 # 2198 # 2494 # 2482


Cumulative Revenue growth Comment
Harvard Bioscience Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Harvard Bioscience Inc 's annual Revenue decline would be -0.37% year on year to $88 millions.

In the Healthcare sector 427 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2340 to 3190.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 18
Healthcare Sector # 428
Overall # 3190

Revenue TTM Y/Y Growth Statistics
High Average Low
25.72 %
 -1.14 %
-16.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 405
S&P 500 # 2838
Cumulative Revenue growth Comment
Harvard Bioscience Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Harvard Bioscience Inc 's annual Revenue fall would be -0.37% year on year to $88 millions.

In the Healthcare sector 427 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2340 to 3190.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 18
Healthcare Sector # 428
Overall # 3190

Revenue TTM Y/Y Growth Statistics
High Average Low
25.72 %
-1.14 %
-16.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 405
S&P 500 # 2838




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HBIO's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions
Milestone Scientific Inc 22.28%$ 22.276 millions
Alpha Teknova Inc 22.05%$ 22.045 millions
X4 Pharmaceuticals Inc21.64%$ 21.642 millions
Exagen Inc 21.63%$ 21.629 millions
Adaptive Biotechnologies Corporation21.53%$ 21.526 millions


About Harvard Bioscience Inc Revenue Growth Rates (HBIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Harvard Bioscience Inc (CIK 1123494).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-26-005425
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Harvard Bioscience Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.